查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1785837

雙胍類藥物的全球市場

Biguanides
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 268 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球雙胍類藥物市場規模將達到 59 億美元

全球雙胍類藥物市場規模預計在2024年為51億美元，預計到2030年將達到59億美元，在分析期內（2024-2030年）的複合年成長率為2.5%。Metformin是本報告分析的細分市場之一，預計其複合年成長率為3.1%，到分析期結束時將達到35億美元。苯乙雙胍細分市場在分析期間的複合年成長率預計為1.7%。

美國市場規模估計為 14 億美元，中國市場預計複合年成長率為 5.0%

美國雙胍類藥物市場規模預計在2024年達到14億美元。作為世界第二大經濟體，中國預計到2030年市場規模將達到11億美元，在2024-2030年的分析期間內，複合年成長率為5.0%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為0.9%和1.9%。在歐洲，預計德國市場的複合年成長率為1.4%。

全球雙胍類藥物市場－主要趨勢與促進因素摘要

為什麼雙胍類是糖尿病和抗生素治療的重要組成部分？

雙胍類藥物主要用於治療第2型糖尿病，因其能夠降低血糖值並改善胰島素敏感性，一直是糖尿病管理的基石。Metformin是處方最廣泛的雙胍類藥物，因其促進周邊葡萄糖攝取並降低肝臟葡萄糖生成的作用而得到世界公認。隨著全球第二型糖尿病和代謝紊亂的盛行率不斷上升，醫療保健專業人員正在尋求經濟高效且可靠的治療方法，這推動了對雙胍類藥物的需求穩步成長。此外，雙胍類藥物在糖尿病治療之外也展現出廣闊的前景，新興研究顯示其在抗衰老、癌症治療和心血管疾病預防方面具有潛在的應用前景。

雙胍類藥物除了在METABOLIC INC.健康中發揮作用外，還因其抗菌特性而被廣泛應用，尤其是在消毒劑和防腐劑中。洛赫西定是一種雙胍類化合物，是醫用防腐劑、口腔衛生產品和外科消毒劑的關鍵成分。它對細菌、真菌和病毒具有廣泛的抗菌活性，使其成為醫院感染控制和個人護理應用的必需品。隨著人們對抗生素抗藥性的擔憂日益加劇，製藥、醫療保健和消費者衛生市場對雙胍類等替代抗菌解決方案的需求日益成長。雙胍類藥物仍然是代謝疾病管理和感染預防的關鍵組成部分，目前正在進行的臨床研究正在探索新的治療應用。

科技進步如何增強雙胍類療法？

製劑和藥物輸送系統的創新顯著提高了雙胍類藥物的療效、生物有效性和安全性。該領域最顯著的進展之一是Metformin緩釋性(ER) 製劑的開發，該製劑通過減少胃腸道副作用和最大限度地減少多劑量的需要，提高了患者的服藥依從性。這些製劑可增強藥物吸收並提供更穩定的血糖控制，使其成為長期糖尿病管理的首選方案。此外，雙胍類藥物與鈉-葡萄糖協同共同輸送體蛋白-2 (SGLT2) 抑制劑或Dipeptidyl Peptidase-4 (DPP-4) 抑制劑聯合治療的研究正在改善複雜代謝疾病患者的預後。

另一項重大突破是雙胍類藥物在癌症和神經退化性疾病等新治療領域的探索。最近的研究表明，Metformin透過抑制細胞能量代謝和抑制腫瘤生長而具有抗癌特性。此外，臨床前研究表明Metformin可能具有神經保護特性，並可能在減緩阿茲海默症和其他神經退化性疾病的進展方面發揮作用。在抗菌劑領域，基於奈米顆粒的遞送系統的進步提高了洛赫西定在預防醫院內感染和改善創傷治療的有效性。隨著製藥和生技公司繼續在研發方面投入，雙胍類藥物有望擴展到新的醫療應用領域，並在現代醫學中發揮越來越重要的作用。

哪些行業趨勢將推動雙胍類藥物市場的成長？

全球雙胍類藥物市場正穩步成長，這得益於糖尿病患病率的上升、抗菌解決方案需求的不斷成長以及新興治療領域應用的不斷拓展。影響市場發展的最重要趨勢之一是第2型糖尿病患者的快速成長，尤其是在新興經濟體，生活方式的改變和都市化導致代謝紊亂的發生率居高不下。隨著各國政府和醫療機構將糖尿病管理置於優先地位，Metformin因其價格實惠且療效確切，仍是首選藥物。此外，預防性醫療保健的日益重視也促進了篩檢和早期診斷的增多，進一步推動了對雙胍類藥物的需求。

影響市場的另一個關鍵趨勢是人們越來越重視醫療保健和消費者衛生領域的感染控制。 COVID-19 疫情提高了人們對抗菌素抗藥性和有效消毒劑需求的認知，導致醫院、牙科診所和個人衛生產品中雙胍類消毒劑（如洛赫西定）的使用增加。此外，遠端醫療和網路藥局的擴張改善了雙胍類藥物的可近性，確保了市場的持續成長。隨著研究人員開發出基於基因和代謝特徵最佳化治療的標靶治療，雙胍類藥物在個人化醫療（尤其是精準糖尿病護理）中的探索也越來越受到關注。隨著對創新且具成本效益的醫療保健解決方案的需求持續成長，雙胍類市場預計將擴展到多種治療和預防應用。

影響雙胍類藥物市場未來發展的關鍵成長動力有哪些？

雙胍類藥物市場的成長受到多種因素的推動，包括糖尿病盛行率的上升、藥物研發投入的增加以及在糖尿病以外治療領域的應用不斷擴大。其中一個主要的成長要素是持續的全球糖尿病疫情，預計2023年將影響超過5.37億成年人。Metformin價格實惠且在臨床上長期取得成功，使其成為糖尿病管理策略的關鍵組成部分，尤其是在難以獲得先進療法的新興市場。此外，製藥公司正在探索新的藥物組合和下一代雙胍類藥物類似物，以提高療效並最大程度地減少副作用。

影響市場的另一個關鍵促進因素是對抗菌和感染控制解決方案日益成長的需求。隨著院內感染 (HAI) 成為重大公共衛生風險，對洛赫西定類抗菌劑和消毒劑的需求也日益成長。此外，人們對抗菌素抗藥性的認知不斷提高，推動了對能夠增強抗抗藥性病原體功效的雙胍類衍生物的研究。雙胍類藥物在腫瘤學、神經保護和長壽研究中的潛在作用也激發了生物技術和製藥公司的興趣，帶來了新的投資機會。隨著科學進步不斷開發新的治療應用，以及監管機構支持擴大適應症，雙胍類藥物市場正在經歷持續成長，鞏固了其在代謝和抗菌藥物領域的重要性。

部分

類型（Metformin、苯乙雙胍）、分銷管道（零售藥局分銷管道、醫院分銷管道、其他分銷管道）

受訪公司範例

  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals
  • Intas Pharmaceuticals
  • Lupin Pharmaceuticals, Inc.
  • Merck KGAA
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris, Inc.
  • Wockhardt Ltd.
  • Zydus Lifesciences Ltd.

人工智慧整合

利用檢驗的專家內容和 AI 工具轉變您的市場和競爭情報。

Global 特定產業產業SLM 的典型規範，而是建立了一個從世界各地專家收集的內容庫，包括影片錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP29554

Global Biguanides Market to Reach US$5.9 Billion by 2030

The global market for Biguanides estimated at US$5.1 Billion in the year 2024, is expected to reach US$5.9 Billion by 2030, growing at a CAGR of 2.5% over the analysis period 2024-2030. Metformin, one of the segments analyzed in the report, is expected to record a 3.1% CAGR and reach US$3.5 Billion by the end of the analysis period. Growth in the Phenformin segment is estimated at 1.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.4 Billion While China is Forecast to Grow at 5.0% CAGR

The Biguanides market in the U.S. is estimated at US$1.4 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.1 Billion by the year 2030 trailing a CAGR of 5.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Global Biguanides Market - Key Trends & Drivers Summarized

Why Are Biguanides a Critical Component in Diabetes and Antimicrobial Treatments?

Biguanides, a class of medications primarily used to treat type 2 diabetes, have remained a cornerstone of diabetes management due to their effectiveness in lowering blood glucose levels and improving insulin sensitivity. Metformin, the most widely prescribed biguanide, has gained global recognition for its role in reducing hepatic glucose production while enhancing peripheral glucose uptake. With the increasing prevalence of type 2 diabetes and metabolic disorders worldwide, the demand for biguanides continues to rise as healthcare providers seek cost-effective and reliable treatment options. Additionally, biguanides have shown promise beyond diabetes treatment, with emerging research suggesting potential applications in anti-aging, cancer therapy, and cardiovascular disease prevention.

Beyond their role in metabolic health, biguanides are also widely used for their antimicrobial properties, particularly in disinfectants and antiseptics. Chlorhexidine, a biguanide-based compound, is a key ingredient in medical-grade antiseptics, oral hygiene products, and surgical disinfectants. Its broad-spectrum antimicrobial activity against bacteria, fungi, and viruses has made it indispensable in hospital infection control and personal care applications. As concerns about antibiotic resistance grow, the demand for alternative antimicrobial solutions like biguanides is expanding across pharmaceutical, healthcare, and consumer hygiene markets. With ongoing clinical research exploring new therapeutic uses, biguanides are positioned to remain a vital component of both metabolic disease management and infection prevention.

How Are Technological Advancements Enhancing Biguanide-Based Treatments?

Innovations in pharmaceutical formulation and drug delivery systems are significantly improving the efficacy, bioavailability, and safety profile of biguanide-based treatments. One of the most notable advancements in this field is the development of extended-release (ER) metformin formulations, which offer better patient adherence by reducing gastrointestinal side effects and minimizing the need for multiple daily doses. These formulations enhance drug absorption and provide more stable glucose control, making them a preferred option for long-term diabetes management. Additionally, research into combination therapies that pair biguanides with sodium-glucose co-transporter-2 (SGLT2) inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors is driving improved treatment outcomes for patients with complex metabolic conditions.

Another major breakthrough is the exploration of biguanides in new therapeutic areas, including oncology and neurodegenerative diseases. Recent studies have suggested that metformin possesses anti-cancer properties by inhibiting cellular energy metabolism and reducing tumor growth. Additionally, preclinical research indicates that biguanides may have neuroprotective effects, potentially playing a role in delaying the progression of Alzheimer’s disease and other neurodegenerative disorders. In the antimicrobial sector, advancements in nanoparticle-based delivery systems are enhancing the effectiveness of chlorhexidine in preventing hospital-acquired infections and improving wound healing. As pharmaceutical and biotech companies continue to invest in research and development, biguanide-based treatments are expected to expand into new medical applications, reinforcing their relevance in modern medicine.

Which Industry Trends Are Driving Growth in the Biguanides Market?

The global biguanides market is experiencing steady growth due to rising diabetes prevalence, increasing demand for antimicrobial solutions, and expanding applications in emerging therapeutic fields. One of the most influential trends shaping the market is the surge in type 2 diabetes cases, particularly in developing economies where lifestyle changes and urbanization have led to a higher incidence of metabolic disorders. With governments and healthcare organizations prioritizing diabetes management, metformin remains a first-line therapy due to its affordability and proven efficacy. Additionally, the growing emphasis on preventive healthcare has led to increased screening and early diagnosis, further driving demand for biguanide-based treatments.

Another key trend influencing the market is the rising focus on infection control in healthcare and consumer hygiene. The COVID-19 pandemic heightened awareness of antimicrobial resistance and the need for effective disinfectants, leading to increased use of biguanide-based antiseptics like chlorhexidine in hospitals, dental care, and personal hygiene products. Moreover, the expansion of telemedicine and e-pharmacies has improved access to biguanide medications, ensuring continued market growth. The exploration of biguanides in personalized medicine, particularly in precision diabetes care, is also gaining traction as researchers develop targeted therapies that optimize treatment based on genetic and metabolic profiles. As the demand for innovative and cost-effective healthcare solutions continues to rise, the biguanides market is expected to expand across multiple therapeutic and preventive applications.

What Are the Key Growth Drivers Shaping the Future of the Biguanides Market?

The growth in the biguanides market is driven by several factors, including increasing diabetes prevalence, rising investments in drug research, and expanding applications in non-diabetes therapeutic areas. One of the primary growth drivers is the ongoing global diabetes epidemic, with over 537 million adults estimated to have diabetes in 2023. The affordability and long-standing clinical success of metformin make it a critical component of diabetes management strategies, particularly in emerging markets with limited access to advanced therapies. Additionally, pharmaceutical companies are exploring novel drug combinations and next-generation biguanide analogs to enhance therapeutic efficacy and minimize side effects.

Another key driver shaping the market is the growing need for antimicrobial and infection control solutions. With hospital-acquired infections (HAIs) posing a significant public health risk, the demand for chlorhexidine-based antiseptics and disinfectants continues to rise. Furthermore, the increasing awareness of antimicrobial resistance has prompted research into biguanide derivatives with enhanced efficacy against drug-resistant pathogens. The potential role of biguanides in oncology, neuroprotection, and longevity research is also driving interest from biotech and pharmaceutical firms, leading to new investment opportunities. As scientific advancements continue to unlock new therapeutic applications and regulatory agencies support expanded indications, the biguanides market is poised for sustained growth, solidifying its importance in both metabolic and antimicrobial medicine.

SCOPE OF STUDY:

The report analyzes the Biguanides market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Metformin, Phenformin); Distribution Channel (Retail Pharmacies Distribution Channel, Hospitals Distribution Channel, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

  • Biocon Ltd.
  • Boehringer Ingelheim International GmbH
  • Bristol-Myers Squibb
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals
  • Intas Pharmaceuticals
  • Lupin Pharmaceuticals, Inc.
  • Merck KGAA
  • Sanofi
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Viatris, Inc.
  • Wockhardt Ltd.
  • Zydus Lifesciences Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Biguanides - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Diabetes Prevalence Throws the Spotlight on Biguanides as a First-Line Therapeutic Class
    • Growing Demand for Cost-Effective Antidiabetic Drugs Drives Widespread Use of Metformin-Based Biguanides
    • Increased Focus on Metabolic Health and Pre-Diabetes Management Expands Addressable Market Opportunity for Biguanide Compounds
    • Scientific Advancements in Repurposing Biguanides for Cancer, Aging, and Cardiovascular Health Strengthen Long-Term Growth Prospects
    • Regulatory Endorsement of Metformin as a Gold-Standard Treatment Drives Continued Global Adoption
    • Emerging Research on Biguanides in Geroprotection and Longevity Science Spurs New Therapeutic Applications
    • Surge in Demand for Antimicrobial Agents Drives Biguanide Usage in Hospital-Grade Disinfectants and Antiseptics
    • Expansion of Personal Hygiene and Surface Disinfection Markets Strengthens the Business Case for Biguanide-Based Biocides
    • Growing Emphasis on Infection Control in Healthcare Facilities Fuels Demand for Biguanide Antiseptics Like Chlorhexidine
    • Interest in Combination Therapies and Drug Synergies Enhances Use of Biguanides in Multimodal Treatment Regimens
    • Rising Geriatric Population and Polypharmacy Trends Sustain Long-Term Demand for Well-Tolerated Biguanide Drugs
    • Low Cost and High Therapeutic Index of Biguanides Support Their Role in Essential Drug Lists and Public Health Programs
    • Emerging Interest in Biguanides for Weight Management and Insulin Sensitivity Strengthens Consumer and Clinical Demand
    • Increasing Pharmaceutical R&D Investments Drive Innovation in Modified-Release and Combination Formulations of Biguanides
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Biguanides Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Biguanides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Biguanides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Metformin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Metformin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Metformin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Phenformin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Phenformin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Phenformin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospitals Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospitals Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 21: USA Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: USA 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 23: USA Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: USA 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: Canada Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: Canada 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: Canada 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Japan Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Japan 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Japan 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: China Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: China 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 41: China Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: China 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Biguanides by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 45: Europe Historic Review for Biguanides by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Europe 15-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Europe 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 53: France Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: France Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: France 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: France 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 59: Germany Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Germany Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Germany 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Germany 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 65: Italy Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Italy Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Italy 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Italy 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 71: UK Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: UK Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: UK 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: UK 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 77: Spain Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Spain Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Spain 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Spain 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 83: Russia Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Russia Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Russia 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Russia 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 89: Rest of Europe Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Rest of Europe Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Rest of Europe 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 95: Asia-Pacific Recent Past, Current & Future Analysis for Biguanides by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 96: Asia-Pacific Historic Review for Biguanides by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Asia-Pacific 15-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 104: Australia Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Australia Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Australia 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Australia 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 110: India Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: India Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: India 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 113: India Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: India 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 116: South Korea Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: South Korea Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: South Korea 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: South Korea 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 122: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Rest of Asia-Pacific Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Rest of Asia-Pacific 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 128: Latin America Recent Past, Current & Future Analysis for Biguanides by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 129: Latin America Historic Review for Biguanides by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Latin America 15-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Latin America 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Latin America 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 137: Argentina Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Argentina Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Argentina 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Argentina 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 143: Brazil Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Brazil Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Brazil 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Brazil 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 149: Mexico Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Mexico Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Mexico 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Mexico 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 155: Rest of Latin America Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Latin America Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Latin America 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 161: Middle East Recent Past, Current & Future Analysis for Biguanides by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 162: Middle East Historic Review for Biguanides by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Middle East 15-Year Perspective for Biguanides by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Middle East 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Middle East 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 170: Iran Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Iran Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Iran 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Iran 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 176: Israel Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Israel Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Israel 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Israel 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 182: Saudi Arabia Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Saudi Arabia Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Saudi Arabia 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 188: UAE Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: UAE Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: UAE 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: UAE 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 194: Rest of Middle East Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Middle East Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Middle East 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • Biguanides Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 200: Africa Recent Past, Current & Future Analysis for Biguanides by Type - Metformin and Phenformin - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Africa Historic Review for Biguanides by Type - Metformin and Phenformin Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Africa 15-Year Perspective for Biguanides by Type - Percentage Breakdown of Value Sales for Metformin and Phenformin for the Years 2015, 2025 & 2030
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Biguanides by Distribution Channel - Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Africa 15-Year Perspective for Biguanides by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Hospitals Distribution Channel and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION